Perspectives on Practice Changing Research 2023
Moderated by Dr. Hertzel Gerstein, this accredited online symposium features a review of the key scientific developments in endocrinology and diabetes over the past year. Our faculty will synthesize and discuss within the Canadian context research from major conferences and papers.
Topics covered:
• Medical therapy for non-diabetes obesity to improve patient outcomes: Ongoing trials in prevention of diabetes, MAFLD, and cardiovascular events, and quality of life enhancement
• Novelties in hypoparathyroidism: Current and future therapies
• Novel approaches to insulin therapy: Challenges and opportunities with new basal insulins
• Benefits and risks of androgen replacement in middle-aged and older men with low testosterone levels
1. Review and synthesize key scientific developments in diabetes and endocrinology over the past year
2. Evaluate the relevance and implications for diabetes management within a Canadian context
3. Identify important elements of emerging research that can be applied to clinical practice
Biography:
Dr. Claudia Gagnon practices as an adult endocrinologist at CHU de Québec. She is also an Associate Professor in the Department of Medicine at Université Laval and a clinician-researcher at CHU de Québec-Université Laval Research Centre and at Québec Heart and Lung Institute Research Centre. She is a scholar of the Fonds de recherche du Québec-Santé. After completing residency training in adult endocrinology at Université de Sherbrooke in 2006, she undertook a 3-year fellowship in metabolic bone diseases and phosphocalcic metabolism in Melbourne, Australia.
Her research focuses on the impact of obesity, diabetes and their treatments (in particular bariatric surgery) on bone health. She received funding from Diabetes Canada, Diabète Québec, and the Canadian Institutes of Health Research. She published over 60 articles in peer-reviewed journals, some of which were cited in the most recent bone guidelines of the American Society for Bariatric and Metabolic Surgery. She has been awarded the 2022 CSEM Young Investigator Award, the 2019 Jean-Davignon Young Investigator Award from the Cardiometabolic, diabetes and obesity FRQ-S network, the 2017 research prize of the Fédération des médecins spécialistes du Québec, and the 2015 New Investigator Award at the International Symposium on the Nutritional Aspects of Osteoporosis. She is the Vice-Chair of the Scientific Advisory Council of Osteoporosis Canada since September 2021. She is also involved in various national and international committees including Diabète Québec, Diabetes Canada, Osteoporosis Canada, and is involved in the upcoming international guidelines on vitamin D supplementation after bariatric surgery.
Google scholar web link:
https://scholar.google.com/citations?hl=en&user=7TDGCCUAAAAJ
CHU de Québec-Université Laval web page: http://www.crchudequebec.ulaval.ca/en/research/researchers/claudia-gagnon/
Biography:
Dr Dutton is an endocrinologist at The Ottawa Hospital in the Division of Endocrinology & Metabolism and is an assistant professor at the University of Ottawa. She completed a clinical and research fellowship in Bariatric Medicine, as well as a Master of Science degree in Clinical Epidemiology, both at the University of Ottawa. The focus of her practice is in the areas of weight management, bariatric medicine, and lifestyle medicine. Dr Dutton has certifications from the American Board of Obesity Medicine (ABOM) and the American Board of Lifestyle Medicine (ABLM).
Biography:
Dr. Christopher Tran is the program director for the Endocrinology and Metabolism residency training program at the University of Ottawa. He is an assistant professor at the University of Ottawa and received Educator of the Year (Preclerkship) and the 2022 Canadian Association Medical Education Certificate of Merit awards for his contributions to medical education.
Conflicts of Interest:
I do not have a relationship with a for-profit and/or not-for-profit organization to disclose.
Biography:
Dr. Hertzel C. Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research. He is also Director of the Division of Endocrinology & Metabolism, Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute. He has received several honors including the Canadian Diabetes Association’s Young Scientist Award (1999), Frederick G. Banting award (1999), Charles H. Best award (2007) and Lifetime Achievement Award (2012). Dr. Gerstein has designed and led many large simple international cardiovascular outcome trials in people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. His research spans over 50 countries, and has been funded by the Canadian Institutes of Health Research, the National Institutes of Health, the Heart and Stroke Foundation, the Canadian Diabetes Association and Industry. Dr. Gerstein has published more than 300 papers, editorials and commentaries, mainly on diabetes-related issues.
Conflicts of Interest:
Membership on advisory boards or speakers’ bureaus – Sanofi, Lilly, Boehringer Ingelheim, DKSH, Zuellig, Roche – speaker.
Sanofi, Lilly, Novo Nordisk, Abbott, Boehringer Ingelheim, Pfizer, Kowa, Hanmi – Consulting.
Lilly, Sanofi, Novo Nordisk, Merck, AstraZeneca – grants to his institution for research.
Novo Nordisk
Eli Lilly
